精选 · 医疗保健

Biotech

由 InspectStocks 整理Published 2026年10月14日19 companies0 followers

Drug developers with approved medicines, built mainly on biologic and genetic science.

借助 AI 模型分组，并经我们的编辑审核。每家公司下方的一行说明它为何在这里。

Download image

卡片梯队

股价为 2026年11月11日收盘价，来自 IEX 交易所数据。

Grade mix

A 8B 4C 5D 1F 1

Revenue growing

18 of 19

Free cash flow growing

13 of 18

Median price move, 1 year

+29.0%

Sort by

VRTXVERTEX PHARMACEUTICALS INC / MA
BiotechnologyMarket cap US$138.7BP/E 35.22
US$547.02+26.0%1Y
Since added +12.7%
B+
成长与现金
强劲增长
Business trend
平稳
Business quality
强
Getting better
在改善
Revenue
US$13B+10.5%
Profit
US$4B+8.2%
Free cash flow
US$3.2B-4.0%
Discuss
Why it is here: Develops and sells cystic fibrosis and other medicines
REGNREGENERON PHARMACEUTICALS, INC.
BiotechnologyMarket cap US$101.3BP/E 21.18
US$959.45+41.5%1Y
Since added +27.4%
C+
成长与现金
在增长
Business trend
加速
Business quality
强
Getting better
在改善
Revenue
US$16.9B+18.6%
Profit
US$4.8B+5.2%
Free cash flow
US$3.8B-9.4%
Discuss
Why it is here: Develops and sells antibody therapies for eye, allergy and cancer conditions
GILDGILEAD SCIENCES, INC.
Drug manufacturers generalMarket cap US$210.5B无市盈率（经营亏损）
US$169.73+40.9%1Y
Since added +14.8%
A
成长与现金
强劲增长
Business trend
平稳
Business quality
参差
Getting better
在改善
Revenue
US$31B+6.5%
Profit
-US$3.9B-147.6%
Free cash flow
US$13.8B+50.4%
Discuss
Why it is here: Sells medicines for HIV, liver disease and cancer
ALNYALNYLAM PHARMACEUTICALS, INC.
BiotechnologyMarket cap US$21.4BP/E 68.58
US$159.80-64.7%1Y
Since added -28.6%
B+
成长与现金
强劲增长
Business trend
放缓
Business quality
强
Getting better
在改善
Revenue
US$3.7B+65.2%
Profit
US$2.6B+2,136.9%
Free cash flow
US$465.4M+1,192.7%
Discuss
Why it is here: Develops and sells RNAi therapeutics
BIIBBIOGEN INC.
Drug manufacturers generalMarket cap US$37.5BP/E 109.22
US$253.39+56.9%1Y
Since added +10.7%
A
成长与现金
强劲增长
Business trend
平稳
Business quality
稳健
Getting better
参差
Revenue
US$10.3B+2.3%
Profit
US$347.5M-78.4%
Free cash flow
US$2.1B-10.1%
Discuss
Why it is here: Develops and sells therapies for neurological diseases
INSMINSMED INC
BiotechnologyMarket cap US$26.5B无市盈率（经营亏损）
US$120.64-37.9%1Y
Since added +24.7%
C-
成长与现金
在增长
Business trend
平稳
Business quality
弱
Getting better
参差
Revenue
US$1.5B+240.0%
Profit
-US$605.6M+48.8%
Free cash flow
-US$627.6M+30.7%
Discuss
Why it is here: Develops and sells therapies for rare lung diseases
UTHRUnited Therapeutics Corporation
Drug manufacturers specialty and genericMarket cap US$25.4BP/E 22.48
US$595.58+29.0%1Y
Since added +9.6%
C+
成长与现金
强劲增长
Business trend
放缓
Business quality
强
Getting better
明显改善
Revenue
US$3.2B+1.9%
Profit
US$1.2B-3.2%
Free cash flow
US$867.2M-22.7%
Discuss
Why it is here: Sells therapies for pulmonary arterial hypertension
NBIXNEUROCRINE BIOSCIENCES, INC.
Drug manufacturers specialty and genericMarket cap US$17.6BP/E 25.87
US$174.35+18.7%1Y
Since added +29.0%
A+
成长与现金
强劲增长
Business trend
加速
Business quality
强
Getting better
在改善
Revenue
US$3.7B+38.0%
Profit
US$702.5M+64.1%
Free cash flow
US$1B+75.3%
Discuss
Why it is here: Develops and sells therapies for neurological and endocrine disorders
MRNAModerna, Inc.
BiotechnologyMarket cap US$100.6B无市盈率（经营亏损）
US$248.70+831.1%1Y
Since added +15.0%
C-
成长与现金
在增长
Business trend
加速
Business quality
弱
Getting better
在恶化
Revenue
US$2.5B+13.1%
Profit
-US$2.8B+10.5%
Free cash flow
-US$2B+25.7%
Discuss
Why it is here: Develops mRNA vaccines and therapies
BMRNBioMarin Pharmaceutical Inc
BiotechnologyMarket cap US$11.3BNo P/E
US$58.32+5.4%1Y
Since added +7.3%
B
成长与现金
强劲增长
Business trend
平稳
Business quality
参差
Getting better
在改善
Revenue
US$3.7B+18.1%
Profit
-US$19.1M-103.7%
Free cash flow
US$557.9M-33.0%
Discuss
Why it is here: Develops and sells therapies for rare genetic diseases
INCYINCYTE CORPORATION
BiotechnologyMarket cap US$24.9BP/E 65.01
US$122.23+12.9%1Y
Since added +12.6%
C
利润与账面价值
在增长
Business quality
参差
Getting better
明显改善
Revenue
US$6B+24.9%
Profit
US$403.4M-66.1%
Free cash flow
US$892.1MNo comparable year
Discuss
Why it is here: Develops and sells oncology and inflammation therapies
EXELEXELIXIS, INC.
BiotechnologyMarket cap US$17.3BP/E 21.17
US$70.71+62.2%1Y
Since added +18.8%
A+
成长与现金
强劲增长
Business trend
平稳
Business quality
强
Getting better
在改善
Revenue
US$2.5B+9.1%
Profit
US$885.1M+30.6%
Free cash flow
US$1.2B+48.9%
Discuss
Why it is here: Develops and sells cancer therapies
BNTXBioNTech SE
BiotechnologyMarket cap US$22B无市盈率（经营亏损）
US$87.64-21.5%1Y
Since added -1.5%
F
成长与现金
参差
Business trend
收缩
Business quality
参差
Getting better
在改善
Revenue
US$2.7B-23.2%
Profit
-US$1.6B-157.7%
Free cash flow
US$314M+456.5%
Discuss
Why it is here: Develops mRNA vaccines and cancer therapies
JAZZJazz Pharmaceuticals plc
BiotechnologyMarket cap US$15.9BP/E 80.84
US$248.18+81.5%1Y
Since added +18.0%
A
成长与现金
强劲增长
Business trend
平稳
Business quality
参差
Getting better
在改善
Revenue
US$4.7B+13.5%
Profit
US$206M+155.9%
Free cash flow
US$1.6B+21.3%
Discuss
Why it is here: Develops and sells neuroscience and oncology therapies
HALOHALOZYME THERAPEUTICS, INC.
BiotechnologyMarket cap US$11.6BP/E 25.36
US$101.69+44.0%1Y
Since added -7.2%
A+
成长与现金
强劲增长
Business trend
平稳
Business quality
强
Getting better
在改善
Revenue
US$1.8B+45.0%
Profit
US$485.4M-18.5%
Free cash flow
US$885.9M+47.1%
Discuss
Why it is here: Licenses drug delivery technology and sells enzyme-based therapies
ASNDAscendis Pharma A/S
BiotechnologyMarket cap US$16.1B无市盈率（经营亏损）
US$259.10+30.1%1Y
Since added +16.0%
D
利润与账面价值
参差
Business quality
参差
Getting better
在改善
Revenue
US$1.2B+113.4%
Profit
-US$254.8M+39.7%
Free cash flow
-US$293.2M+54.2%
Discuss
Why it is here: Develops and sells endocrinology rare disease therapies
BBIOBridgeBio Pharma, Inc.
BiotechnologyMarket cap US$15.5B无市盈率（经营亏损）
US$79.53+20.1%1Y
Since added +25.6%
B
成长与现金
强劲增长
Business trend
平稳
Business quality
参差
Getting better
在恶化
Revenue
US$945.5M+167.3%
Profit
-US$573.8M+28.6%
Free cash flow
-US$369.8M+36.9%
Discuss
Why it is here: Develops therapies for genetic diseases
CORTCORCEPT THERAPEUTICS INC
BiotechnologyMarket cap US$8.2BP/E 58.68
US$74.52-4.9%1Y
Since added -36.7%
A+
成长与现金
强劲增长
Business trend
加速
Business quality
强
Getting better
参差
Revenue
US$963.6M+30.0%
Profit
US$162.3M+52.9%
Free cash flow
US$194.6M+19.2%
Discuss
Why it is here: Develops and sells cortisol-modulating therapies
KRYSKrystal Biotech, Inc.
BiotechnologyMarket cap US$9.2BP/E 41.90
US$308.82+52.1%1Y
Since added -3.9%
A+
成长与现金
强劲增长
Business trend
平稳
Business quality
强
Getting better
在改善
Revenue
US$470M+26.0%
Profit
US$225.2M+13.2%
Free cash flow
US$310.1M+87.3%
Discuss
Why it is here: Develops and sells topical gene therapies for rare diseases

Green and red compare each figure with the same window a year earlier. Grades and checks are the company page's own; nothing here is a recommendation.

DiscussionNo comments yet

Be civil and stick to the companies. Comments are opinions, not advice.

Lists are their owners' own, and notes and comments are opinions. Grades describe businesses from their filings; nothing here is a recommendation to buy or sell.